neoadjuvant chemoradiotherapy
Showing 1 - 25 of 3,984
Rectal Cancer Trial (Neoadjuvant Chemoradiotherapy, Total Neoadjuvant Therapy)
Not yet recruiting
- Rectal Cancer
- Neoadjuvant Chemoradiotherapy
- Total Neoadjuvant Therapy
- (no location specified)
Oct 24, 2023
Esophageal Cancer, Active Surveillance, Neoadjuvant Chemoradiotherapy Trial in Rotterdam (Active surveillance)
Active, not recruiting
- Esophageal Cancer
- +3 more
- Active surveillance
-
Rotterdam, Zuid-Holland, NetherlandsErasmus MC, University Medical Center
Jul 11, 2023
Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)
Not yet recruiting
- Locally Advanced Rectal Cancer
- AK104
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 5, 2023
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and
Not yet recruiting
- Colorectal Neoplasms
-
Beijing, Xicheng Dis, ChinaBeijing Friendship Hospital, Capital medical University
Sep 5, 2023
Esophageal Cancer Trial (Hypofractionated radiotherapy)
Not yet recruiting
- Esophageal Cancer
- Hypofractionated radiotherapy
- (no location specified)
Jan 18, 2023
Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to
Active, not recruiting
- Esophageal Cancer
- follow up
-
Guangzhou, Guangdong, ChinaJianhua Fu
Sep 24, 2023
Rectal Cancer Trial in Shanghai (Total Neoadjuvant Chemoradiotherapy)
Recruiting
- Rectal Cancer
- Total Neoadjuvant Chemoradiotherapy
-
Shanghai, Shanghai, ChinaFudan University Zhongshan Hospital
Sep 28, 2022
Rectal Cancer Patients Based on ctDNA-MRD Technology
Recruiting
- Rectal Adenocarcinoma
- +3 more
- MRD detection
-
Guangzhou, Guangdong, ChinaWeiWei Xiao
Jul 31, 2023
Rectal Cancer, Lymph Node Cancer Metastatic Trial in Milan (ICG-guided lymphadenectomy)
Recruiting
- Rectal Cancer
- Lymph Node Cancer Metastatic
- ICG-guided lymphadenectomy
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
May 15, 2023
Esophageal Cancer Trial in Moscow (Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.,
Recruiting
- Esophageal Cancer
- Patients undergoing neoadjuvant chemoradiotherapy plus Ivory-Lewis or McKeown esophagectomy.
- Patients undergoing neoadjuvant chemotherapy plus Ivory-Lewis or McKeown esophagectomy
-
Moscow, Russian FederationN.N. Blokhin National Medical Research Center of Oncology
Oct 2, 2022
Neoadjuvant Chemoradiotherapy Combined With Surgery in
Active, not recruiting
- Colon Neoplasm
- Short-term neoadjuvant chemoradiotherapy
-
Xi'an, Shanxi, ChinaGeneral Surgery Gastrointestinal Department,Tang-Du of Fourth Mi
Nov 9, 2022
Locally Advanced, High-Risk, Rectal Cancer Trial in Guangzhou (Toripalimab, short-term radiotherapy, Oxaliplatin)
Not yet recruiting
- Locally Advanced
- +3 more
- Toripalimab
- +3 more
-
Guangzhou, Guangdong, ChinaNanfang Hospital Southern Medical University
May 17, 2023
Locally Advanced Rectal Cancer Trial in Beijing (capecitabine, tislelizumab, thymalfasin)
Not yet recruiting
- Locally Advanced Rectal Cancer
- capecitabine
- +3 more
-
Beijing, China
- +1 more
Sep 21, 2023
Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1 Trial in Changchun (nCRT ? (CapeOX+Sintilimab)×6 ?
Not yet recruiting
- Locally Advanced Rectal Cancer
- +2 more
- nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
-
Changchun, Ji Lin, ChinaFirst Hospital of Jilin University
Aug 11, 2023
Esophageal Cancer Trial in Taoyuan (PET/MRI)
Completed
- Esophageal Cancer
- PET/MRI
-
Taoyuan, TaiwanLinkou Chang Gung Memorial Hospital
May 9, 2023
Rectal Tumors Trial in Larissa (Neoadjuvant Chemoradiotherapy, Adjuvant Chemotherapy, Consolidation Chemotherapy)
Not yet recruiting
- Rectal Neoplasms
- Neoadjuvant Chemoradiotherapy
- +2 more
-
Larissa, GreeceDepartment of Surgery, University Hospital of Larissa
Aug 10, 2022
Oncological Impact of Lateral Nodes in Rectal Cancer
Completed
- Colorectal Adenocarcinoma
- Neoadjuvant chemoradiotherapy (CRT)
- (no location specified)
Oct 20, 2022
Adenocarcinoma of Esophagogastric Junction Trial in Beijing (neoadjuvant Radiation plus SOX and PD-1 antibody)
Not yet recruiting
- Adenocarcinoma of Esophagogastric Junction
- neoadjuvant Radiation plus SOX and PD-1 antibody
-
Beijing, Beijing, ChinaPeking University People's Hospital
Aug 15, 2022
Toxicity, Drug Trial in Hefei (neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery)
Recruiting
- Toxicity, Drug
- neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
-
Hefei, Anhui, ChinaAnhui Provicial Hospital
May 1, 2022
Rectal Cancer Trial in Guangzhou (Sintilimab)
Recruiting
- Rectal Cancer
-
Guangzhou, Guangdong, ChinaDepartment of colorectal surgery, the Sixth Affiliated Hospital,
Jul 11, 2022
Esophageal Squamous Cell Carcinoma Trial in Tianjin (biological, drug, radiation)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Pembrolizumab
- +3 more
-
Tianjin, Tianjin, ChinaDepartment of minimally invasive esophageal surgery, Tianjin Med
May 26, 2022
Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1
Recruiting
- Colorectal Neoplasms
- long course radiotherapy + capecitabine + PD-1 monoclonal antibody
-
Beijing, Beijing, ChinaBeijing Friendship Hospital
May 5, 2022
Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III Trial in Shanghai (Neoadjuvant
Recruiting
- Esophageal Squamous Cell Carcinoma Stage II
- Esophageal Squamous Cell Carcinoma Stage III
- Neoadjuvant Chemoradiotherapy
- +2 more
-
Shanghai, ChinaShanghai Zhongshan Hospital
Jun 26, 2022
Rectal Cancer Trial in Wiener Neustadt, Linz, Vienna (Chemoradiotherapy, Ipilimumab, Nivolumab)
Recruiting
- Rectal Cancer
- Chemoradiotherapy
- +2 more
-
Wiener Neustadt, Lower Austria, Austria
- +4 more
Mar 26, 2022
Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer Trial in Guangzhou (drug, radiation, procedure)
Recruiting
- Squamous Cell Esophageal Carcinoma
- +2 more
- Sintilimab
- +4 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 11, 2022